Mesa Laboratories, Inc. has announced impressive financial results for its second quarter of fiscal year 2027, which ended on September 30, 2026. This update is significant as it not only highlights the company's financial health but also marks the first time it has issued full-year guidance, indicating a strong outlook for the future.

For the second quarter, Mesa Laboratories reported a revenue increase of 2.6%, totaling $62.3 million. The company also noted a remarkable 77.6% rise in operating income, reaching $8.4 million, and a 75.3% increase in net income, amounting to $4.3 million. Additionally, the company reported that its non-GAAP Adjusted EBITDA rose by 21.1% to $17.3 million, representing 27.8% of revenues.

These results reflect Mesa's effective strategies in the industrial instruments sector, particularly in quality control solutions and life sciences tools. The company operates across four divisions: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics.

Background

Mesa Laboratories, Inc., incorporated in Colorado, is a leader in the design and manufacture of critical quality control solutions and life sciences tools. The company operates under the Standard Industrial Classification (SIC) code 3823, which pertains to industrial instruments for measurement, display, and control. It trades on the Nasdaq under the ticker symbol MLAB.

Recent filings from the company include a Form 10-Q on November 9, 2026, and a Form 8-K on the same day, both of which provide further insights into its financial performance.

What the Filing Says

The filing details Mesa's financial performance for the three and six months ended September 30, 2026. Notably, the company stated, "Revenues increased 2.6% to $62,336," and highlighted that "operating income increased 77.6% to $8,388." The filing also mentions that the company issued full-year fiscal 2027 guidance for the first time, projecting revenues between $250 million and $255 million and adjusted EBITDA of $66 million to $68 million.

Impact

This update may significantly affect various stakeholders, including investors, employees, and competitors in the industrial instruments sector. Mesa's strong financial performance could enhance investor confidence and attract potential investors looking for growth in the industrial instruments market.

What's Next

The filing does not specify what happens next, but the issuance of full-year guidance suggests that Mesa Laboratories is preparing for continued growth and may provide further updates in upcoming filings or press releases.